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5Abstract 
Background: Perceived food hypersensitivity is a prevalent condition which often remains 
medically unexplained. The etiology of this subjective condition is not fully understood, 
mainly because of a lack of specific diagnostic methods, together with limited knowledge
about underlying pathogenetic mechanisms. Thus, the management of such patients is 
challenging.
Aim: The objective of the present thesis was to assess the potential beneficial effects of seal 
oil on symptoms, and to develop a novel sample protocol to investigate the putative role of 
enteroendocrine secretorial compounds in patients with subjective food hypersensitivity.
Results: In study I, a single dose of duodenal administered seal oil significantly influenced 
neither gastric accommodation, as examined by two dimensional (2D) ultrasonographic 
scanning, nor meal-induced gastrointestinal symptoms, as assessed by visual analogue scales 
(VAS).
After 10 days’ treatment, duodenal administered seal oil, as compared to soy oil, significantly 
reduced meal-induced gastrointestinal symptoms. However, the symptomatic improvement 
was not associated with improvements in gastric accommodation.
In study II, patients with subjective food hypersensitivity received a 10-day open treatment 
with duodenal administered seal oil. Before and after treatment, and 1 month post-treatment, 
the patients filled in the Subjective Health Complaints (SHC) Inventory for non-
gastrointestinal symptoms, the short form of the Nepean Dyspepsia Index (SF-NDI) for 
evaluation of quality of life (QoL), and the Ulcer Esophagitis Subjective Symptoms Scale 
(UESS) score and the Gastrointestinal Symptom Rating Scale (GSRS) for assessment of 
gastrointestinal symptoms. Both intestinal and extra-intestinal complaints were significantly 
improved from baseline, both at 10 and 30 days post-treatment.
In study III, a novel method for direct determination of serotonin (5-HT) in gut lavage fluid 
using liquid chromatography mass spectrometry was achieved. This method was applied in 
study IV.
6In study IV, analyses of chromogranin A (CgA) in serum and 5-HT in gut lavage fluid were 
performed. Serum levels of CgA were significantly lower in patients with subjective food 
hypersensitivity as compared to healthy controls. No significant differences in gut lavage 5-
HT levels were detected between patients with subjective food hypersensitivity, patients with 
inflammatory bowel disease (IBD) and healthy controls.
Conclusion: The present thesis suggests a beneficial effect of duodenal administered seal oil 
on both intestinal and extra-intestinal complaints in patients with subjective food 
hypersensitivity. Impaired gastric accommodation seems to play a limited role in the 
pathophysiology, as the positive effect of seal oil was not associated with improvements in 
gastric accommodation. The mechanism of action may involve the anti-inflammatory and 
immune-modulating properties of the long-chain omega-3 polyunsaturated fatty acids
(PUFAs), and further studies addressing this aspect are needed.
Decreased systemic CgA levels suggest a role for enteroendocrine alterations in the 
pathophysiology of subjective food hypersensitivity, such as impaired enterochromaffin (EC) 
cell function, and the potential of using granins as biomarkers for functional gastrointestinal 
disorders should be explored in future studies. 
Taken together, the hypothesis-generating studies of the present thesis encourage further 
investigations to elucidate causal relationships between the patients’ unexplained symptoms 
and possible pathophysiological mechanisms. 
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1. Introduction 
1.1 Background
The incidence of food hypersensitivity is increasing worldwide. For instance, in Western 
countries, as many as approximately 35 % of the general population report adverse reactions 
to food, but only 1-3 % are medically diagnosed with food allergy [1,2,3]. The observed high 
discrepancy between subjective and medically confirmed food hypersensitivity, is mainly due 
to limited knowledge of the underlying mechanisms of the pathogenesis, and, hence, a lack of
specific diagnostic methods.
The present thesis examines different aspects of subjective food hypersensitivity, such as 
potential beneficial effects of seal oil on the symptomatology, with emphasis on 
gastrointestinal and systemic symptoms, the potential of assessing enteroendocrine secretorial 
compounds for evaluating gastrointestinal pathologies and exploration of a novel sample 
protocol. 
1.2 Definition of food hypersensitivity
In 2003 the Nomenclature Review Committee of the World Allergy Organization proposed an 
updated report [4] on the revised nomenclature for allergy published in 2001 by the European 
Academy of Allergological and Clinical Immunology (EAACI) [5]. The EAACI stated that 
the nomenclature can be used independently of target organ and patient age group, and the 
nomenclature proposed is based on the mechanism initiating the reaction and causing the 
symptoms and signs of an allergic disease. Considering the EAACI’s definition, the word 
“allergy” has previously been faulty used to describe all kinds of unexpected reactions in the 
skin and mucosal surfaces, including reactions to food additives, side-effects of drugs, 
psychological reactions, pharmacological factors, behavioural disorders and others. As 
proposed by the EAACI, hypersensitivity should be used as a collective term to cover all kind 
of adverse reactions, including food allergy and non-allergic food hypersensitivity. The 
definition of the term hypersensitivity should be as follows: Hypersensitivity causes
objectively reproducible symptoms or signs, initiated by exposure to a defined stimulus at a 
dose tolerated by normal subjects [5]. Classical responses to infection, autoimmunity and 
toxic reactions do not accommodate this definition. An important condition for the 
hypersensitivity reaction is that the reproducibility of the symptoms or signs can be confirmed 
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by history, clinical examinations or investigation of causality between symptoms and 
environmental factors to which the patients attribute their symptoms. 
Food hypersensitivity can be divided into two main groups; food allergy and non-allergic food 
hypersensitivity. Based on the immunological mechanism involved, food allergy can be 
further classified into three groups, namely IgE-mediated food allergy, mixed IgE- and non-
IgE-mediated and non-IgE-mediated food allergy (Figure 1) [1,6].
Figure 1. Nomenclature of food hypersensitivity. Illustration by Gülen Arslan Lied.
The diagnostic work-up of suspected food hypersensitivity is based on detailed medical 
history, including familial atopic background and comprehensive physical examination. It is 
important to obtain an accurate history to elucidate the relationship between ingestion of 
specific foods and onset of symptoms, and also to assess the time interval between ingestion 
and appearance of symptoms, the amount of ingested food and to inspect whether same 
foodstuff reproduces symptoms. The standard clinical or laboratory tests include skin prick 
testing (SPT) and in vitro testing for food specific IgE-antibodies [7,8], the atopy patch test 
(APT) [9], and double-blind placebo-controlled food challenge (DBPCFC) [10,11,12,13]; the 
latter representing the gold standard in the diagnostic work-up. The diagnostic accuracy of the 
APT is somewhat controversial, but it is considered a useful tool in diagnosing delayed food 
allergy in children with atopic dermatitis [9,14].
IgE-mediated food allergy
IgE-mediated food allergy is a typical well-known immediate reaction (type I) resulting in 
classical clinical presentation, such as anaphylactic reactions. The most common food allergic 
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disorders put on by IgE-mediated mechanisms are immediate gastrointestinal hypersensitivity, 
oral allergy syndrome, acute urticaria, angiodema, acute bronchospasm and allergic rhinitis. 
Positive SPT and detection of serum food specific IgE are strong indicators for IgE-mediated 
food allergy. The immune system may respond to a foreign protein by producing IgE 
antibodies, thus sensitizing the individual, resulting in positive IgE tests. But this is by no 
means identical with a clinical relevant IgE-mediated allergy. Therefore, in cases of positive 
SPT and in vitro specific IgE, oral food challenges are mandatory before establishing a 
diagnosis of IgE-mediated food allergy. Skin irritations after oral food challenge may be IgE 
mediated, but may also be caused by acids contained in the foods (e.g. citrus fruits). In such 
cases, avoidance is only necessary for the patients’ convenience. 
Non-IgE-mediated food allergy
Non-IgE mediated food allergy initiate immune responses to foods in the absence of specific 
IgE to the causal food protein, at least as verified by routine tests. Non-IgE-mediated food 
allergic reactions has a slower onset (type III-IV reactions) compared to IgE-mediated 
reactions, ranging from a few hours to 48 hours after ingestion of the causative agent [15].
The delayed onset of symptoms often makes it difficult to detect the clinical association 
between offending food and clinical symptoms. Elimination diets and DBPCFC are the 
primary mode of diagnosis, and strict avoidance of the culprit food is often sufficient for the 
patient to manage such food allergies. Eosinophils and T cells seems to play a major role in 
the immune response [16,17]. Gastrointestinal disorders, including allergic eosinophilic 
gastroenteritis, dietary protein-induced enterocolitis and celiac disease, have been associated 
with non-IgE mediated food allergy [15].
Mixed IgE- and non-IgE-mediated food allergy
Allergic eosinophilic esophagitis, gastritis and gastroenterocolitis are characterised by various 
infiltrations with eosinophils in the mucosal, muscular or serosal layer. Eosinophilic 
infiltration and degranulation mediate inflammatory effects by releasing various cytotoxic 
proteins and other lipid mediators together with the release of cytokines. It has been shown 
that peripheral blood T cells in these patients secrete excessive interleukin (IL)-4 and IL-5
compared to controls [18], but the immunopathogenesis of these disorders is poorly 
understood. Elevated serum total IgE or food specific IgE levels are common especially in 
eosinophilic gastritis and gastroenterocolitis [15]. The increased IgE production in these 
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conditions is most likely regulated by cytokines secreted by T cells; especially IL-4 and IL-13 
is known to induce IgE production in humans [19].
Non-allergic food hypersensitivity
Non-allergic food hypersensitivity, previously called food intolerance, refers to non-immune 
mediated food hypersensitivity reactions, at least, immune mechanisms not verified by current 
available techniques. Typical symptoms are flushing, headaches, wheezing, altered bowel 
habits, abdominal pains, bloating, among others. Triggering factors can be divided into 
intrinsic or extrinsic causes; intrinsic causes being enzyme deficiency (e.g. lactase deficiency 
and phenylketonuria), malignancies and psychological factors. Examples of extrinsic causes 
are infections (bacteria, virus, parasites), food additives (glutamate, aspartame, sulphites, 
nitrates, dyes) and pharmacological factors (alcohol, caffeine, histamine, tyramine, serotonin 
and metal contaminants) [5,20]. Patients with non-allergic food hypersensitivity showed
reproducible symptoms in an oral food challenge, despite negative food specific IgE and SPT 
[21].
The above mentioned classification of food hypersensitivity is widely applied in clinical 
practice, but the diagnostic work-up can be challenging and time-consuming. In fact, 
perceived food hypersensitivity most often remains unexplained, despite comprehensive 
medical examination. In the present thesis, the studied patients is referred to as having 
‘subjective food hypersensitivity’, considering the difficulty in allocating them to any of the 
specific diagnosis outlined in Figure 1.
1.3 Symptomatology
The fact that subjective food hypersensitivity often remains unexplained constitutes great 
concern and challenge for both patients and doctors. The patients with subjective food 
hypersensitivity may appear heterogeneous, but today no meaningful diagnostic approach 
exists to detect possible subgroups. The frequency and severity of diverse complaints can vary 
considerably between patients, who typically present diffuse and unspecific symptoms, and 
multiple organ systems are often affected. 
A major part of the symptomatology in subjective food hypersensitivity is related to the 
gastrointestinal tract, with abdominal pain and discomfort, bloating, nausea, and defecation 
disturbances being predominant. The clinical features of the gastrointestinal complaints typify 
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other gastrointestinal disorders, such as irritable bowel syndrome (IBS). In fact, the 
gastrointestinal complaints in unexplained subjective food hypersensitivity usually comply 
with the Rome II criteria for IBS. Also, many IBS patients associate the generation of 
symptoms to food ingestion [22]. Whether the similarity of symptoms in subjective food 
hypersensitivity and IBS is purely coincidental or it is part of a causal relationship has not yet 
been fully established. In our studies, at least 90% of the patients with subjective food 
hypersensitivity have been classified as IBS. Commonly, perceived food hypersensitivity is 
found in around 70 % of patients with IBS [23]. Hence, work up and treatment of IBS is 
central in the caring of our patients. In spite of high prevalence of atopic diseases among 
patients with IBS, classical IgE-mediated food allergy appears of minor importance in these 
patients. On the other hand, the concept “atopic bowel” has been introduced to designate a 
subgroup of patients characterized by atopic diseases and possibly also a high level of serum 
total IgE [24] and a high number of mast cells in the intestinal mucosa that may be related to 
visceral hypersensitivity. Another important subgroup of IBS patients is those with post-
infectious IBS, which comprises around 30% of the total IBS population. Patients with 
persistent complaints following the Giardia lamblia epidemic in Bergen in 2004 are a typical 
example [25].
Our patients with subjective food hypersensitivity have considerably reduced QoL [26] and 
they reported more SHC compared with the general population [27,28]. SHC are defined as 
symptoms or complaints that, despite thorough examination, cannot be fully explained. The 
most frequently reported SHC are musculoskeletal, gastrointestinal and systemic complaints
[27]. Lillestøl and colleagues found high prevalence of anxiety and depression in patients with 
subjective food hypersensitivity, as compared to the general population [29]. Whether mental 
illness is a consequence or the cause of the gastrointestinal and somatic complaints of the 
patients is not clear. Continuous worry and chronic bodily complaints, may over time lead to 
worsen mental illness [30]. On the other hand, psychological stress may modulate visceral 
responses like gut motility and mucosal function through the release of hormones and 
peptides [31,32]. Coexistence of unexplained gastrointestinal and non-gastrointestinal 
complaints suggests multifactorial pathogenic mechanisms, and both gut sensorimotor 
dysfunction and psychological factors may be involved. However, a recent study found that 
psychological factors were not major predictors of symptom severity in patients with 
subjective food hypersensitivity [33].
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1.4 Pathophysiological aspects
1.4.1 Role of nutrition
Nutrition is a critical environmental factor for maintaining a good health, thus the diet play an 
important role in prevention and treatment of different diseases. The evolutionary aspects of 
diet indicate enormous nutritional changes, and the modern diet is characterised by more 
processed and synthetic food, and less fish, fruits and vegetables. One change that has been 
identified in particular is the type and amount of fat consumed. Intake of omega-6 fatty (n-6) 
acids have increased, with major contribution from linoleic acid (LA; 18:2n-6) due to 
extensive use of soybean oil in food production, while the intake of omega-3 (n-3) fatty acids, 
especially the marine derived long chain polyunsaturated fatty acids (LCPUFA) 
eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3), have 
declined. The diet of most westernized societies has been estimated to be deficient in n-3 fatty 
acids with ratios of n-6 to n-3 of 15 to 20:1, whereas optimal ratios have been postulated to be 
1 to 2:1 [34]. Alpha-linolenic acid (ALA; 18:3n-3) and LA are essential fatty acids for 
humans and precursors for the endogenously synthesized EPA and arachidonic acid (AA; 
20:4n-6), respectively. However, the capacity in humans to convert ALA to EPA is somewhat 
disputed [35]. It is therefore important to have a sufficient intake of preformed EPA and DHA 
to maintain or increase the concentration of these fatty acids in tissues. 
LCPUFAs are involved in inflammation, and the link is the metabolites of AA (also known as 
eicosanoids), which are mediators and regulators of inflammatory processes. Eicosanoids are 
synthesized from 20-carbon PUFAs and AA is usually the major substrate due to its high 
content in cell membrane phospholipids. EPA is a metabolic antagonist that inhibits the
metabolism of AA and serves as an alternate substrate for cyclooxygenase (COX) and 
lipooxygenase (LOX). Whereas AA is converted by COX to the pro-inflammatory 
prostaglandin E2 (PGE2), EPA is converted to the homologue PGE3, which is considered far 
less immunologically active. The n-6 derived compounds synthesized in the LOX pathway are 
also more potent triggers of immunological reactions compared to the n-3 derived compounds 
[36]. Selective COX-2 inhibitors are effective drugs in inflammation and pain management, 
but their use has been linked to increased risk of cardiovascular events, like heart-attack, 
thrombosis and stroke [37]. The selective COX-2 inhibitors have been proposed for IBD
patients due to sparing of the mucosal protective properties of COX-1, while retaining the 
anti-inflammatory effect. However, conflicting clinical observations have been reported, and 
the use of selective COX-2 inhibitors in gastrointestinal disorders should be used with same 
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caution as for conventional non-steroidal anti-inflammatory drugs (NSAIDs) [38,39,40]. EPA 
and DHA also inhibit COX-2 activity induced during inflammation [41].
The typical aspects of inflammation or mucosal distortion associated with inflammatory 
disorders of the gut, like IBD, are not present in IBS [42]. However, increased attention has 
been directed towards the role of low-grade inflammation in the intestinal mucosa in patients 
with IBS [43]. Intestinal inflammation may affect the visceral sensory system, leading to 
intestinal motor abnormalities, pain and discomfort, which are typical complaints of patients
with IBS. 
The role of food in the pathophysiology of IBS is unclear, but it is obvious that food by virtue 
of its components is a potent stimulus for gastrointestinal functions like motility and 
secretion. A general dietary advice for IBS patients has been to increase the intake of fiber, 
which are incompletely or indigestible in the small intestine, but partly or totally fermentable 
in the large bowel [44]. Gastrointestinal fermentation may play a role in IBS, thus avoidance 
of fermentable, poorly absorbed carbohydrates is more and more advocated. A recent study by 
Valeur and colleagues indicate that indigestible but fermentable carbohydrates are poorly 
tolerated by patients with IBS and subjective food hypersensitivity [45]. Gibson’s group in 
Australia has introduced the FODMAP (Fermentable Oligo-, Di-, and Monosaccharides and 
Polyols) concept, which, when avoided, has proved to be an effective approach to the 
management of patients with adverse gastrointestinal complaints [46]. FODMAPs are
widespread in the diet. They are characterized by being poorly absorbed, rapidly fermented by 
colonic flora, osmotically active, and they induce distention and discomfort of the gut. A low 
FODMAP diet can be challenging to maintain, due to the range of FODMAPs in the diet, but 
global restriction is recommended [46]. A dietician with good knowledge about the low 
FODMAP diet is therefore required, and should be involved in the treatment and follow-up of 
the patients. Some of the most frequently reported foods to cause gastrointestinal complaints 
in patients with subjective food hypersensitivity are fruits, vegetables and cereal products, 
which all have a high content of FODMAPs. To improve the compliance of the FODMAP 
strategy, further studies are needed to systematically examine the content of FODMAPs in 
foods, and to define cut-off values.  
Probiotics have also been tried extensively as treatment in IBS. Probiotics are live organisms 
that, when ingested in adequate amounts, exert a health benefit on the host [47]. Probiotics are
believed to modify the gut microbiota by changing its composition and metabolic activity, and
to protect against pathogens and stimulate the immune system [48]. A possible role of the gut 
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microbiota in IBS has been suggested, particularly in post-infectious IBS (PI-IBS). Studies 
have demonstrated reduction in abdominal pain and bloating, and an overall better gut 
function in IBS after treatment with specific strains of Lactobacillus and Bifidobacteria
[49,50]. O’Mahony et al. also investigated the immune-modulating effect of probiotics, and 
detected an improvement in the IL-10/IL-12 ratio [49]. However, because the impact of 
probiotics might be species specific, the functioning of different species needs to be further 
investigated, both clinically and mechanistically, in placebo-controlled studies and in well-
defined sub-groups of IBS.
The complex pathophysiology of IBS and subjective food hypersensitivity requires a careful
approach when it comes to treatment, one of which may be through the diet. Although diet 
alone is most likely not sufficient, there are indications that dietary modifications can reduce 
the patients’ complaints. However, due to heterogeneity, a general dietary advice may not 
work for all. Other triggering factors from the diet that potentially can create gastrointestinal 
complaints are food additives, like glutamate, aspartame, and sulphite, and there are also 
pharmacological factors, like alcohol, caffeine, histamine, and serotonin that can affect the gut 
[5,20].
1.4.2 Role of gastric accommodation
The stomach can be divided into two parts when it comes to motor function; the proximal
(fundus and corpus) and the distal (antrum) region. During the interdigestive phase, the 
proximal stomach muscle tone is high, whereas the distal stomach has a recurrent contraction 
pattern, known as the migrating motor complex. Upon food intake, the muscle tone decreases 
and the proximal stomach relaxes, providing a temporarily reservoir of the ingested food. This 
relaxation, called the accommodation reflex, enables the stomach to accommodate the extra 
volume of ingested food, without accompanying rise in the intragastric pressure. 
Postprandially, a tonic contraction of the proximal stomach pushes the food distally, where it 
is mixed and grinded by peristaltic, 3 per minute, contractions (“fed state”), before controlled 
release into the duodenum. The accommodation reflex, which consists of a vagovagal reflex 
pathway, is an important mechanism of normal gastric physiology, and under physiological 
conditions, this adaptive relaxation is not perceived. 
Impaired gastric accommodation of the proximal stomach has been reported in functional 
dyspepsia (FD) [51,52]. The symptoms in FD are related to ingestion of food (especially fat-
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rich food), and they are mainly of gastrointestinal character such as epigastric 
pain/discomfort, nausea, bloating and early satiety. The relationship between impaired gastric 
function and symptoms in FD is not clear, but impaired gastric accommodation has been 
found to be significantly associated to early satiety [53]. The barostat procedure is considered 
as the gold standard in assessing gastric accommodation, but the invasive nature of the 
barostat procedure has limited its application to research facilities. Ultrasound, which is non-
invasive, patient-friendly and a largely available method, is found to be very useful for 
examination of the gastric accommodation response [54,55]. The cause to impaired gastric 
accommodation has not been fully established, but disorders in the sensory apparatus, the 
vagovagal pathway or intrinsic inhibitory innervations are probably involved [56].
Psychological factors, especially anxiety and neuroticism, have also been showed to affect the 
accommodation response [57].
Visceral hypersensitivity is believed to play an important role in the pathogenesis of 
functional gastrointestinal disorders (FGID), and, indeed, increased sensitivity to visceral 
distension has been reported in patients with IBS and FD [58,59,60] . However, a potential 
role of impaired gastric accommodation in IBS needs to be further investigated.
1.4.3 Role of enterochromaffin cells
The name enterochromaffin (EC) cells was introduced by Ciaccio in 1907 to designate the 
cell’s location in the intestinal epithelium and their affinity for chromium salts [61]. The 
endocrine nature of the EC cells was first suggested by Masson in 1914. EC cells constitute 
the largest population of neuroendocrine cells in the gastrointestinal tract. They are distributed 
from the stomach through the colon, and play an important role in several aspects of gut 
function including secretion, motility and sensation. [62,63,64]. The EC cell population 
includes several different sub-populations with morphological differences in shape, 
cytoplasmatic extensions and secretory granules. The main secretory product of EC cells is 
serotonin (5-HT). Over 95 % of the body’s total 5-HT is located within the gut, and 90 % of
that is present in the EC cell, which express the enzymatic machinery, including the rate 
limiting enzyme, tryptophan hydroxylase (TpH), to synthesize 5-HT. The EC cells extend 
from the basal lamina of the crypt epithelium to the lumen of the crypt. Apical cytoplasmic 
extensions with microvilli border protrude into the lumen, and respond to chemical and 
physical alteration of the gut. Hence, the EC cells have been referred to as “taste buds of the 
gut”. Secretory granules are concentrated at the base of the EC cell cytoplasm, and secretion 
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occur mainly basally into the lamina propria, but the cells are bipolar and able to secrete also 
from the apical end, into the gut lumen [62,63,64]. Cytoplasmic extensions with serotonin 
containing granules have also been found basally, often with terminal buttons with 
accumulation of 5-HT [65]. Due to constant turnover of the enteric epithelium including its 
EC cells, nerves cannot form morphological recognizable junctions with EC cells. The 
secretion rate is therefore constitutively high, and even higher upon stimulation. 
Altered 5-HT signalling between EC cells and sensory afferent fibres has been suggested as 
possible mechanisms for alterations in gastrointestinal functions as motility, secretion and
visceral sensation, characteristic of IBS. Changes in key elements in 5-HT signalling, such as 
EC cell count, 5-HT content, TpH message levels, serum 5-HT levels and expression of 
serotonin-selective reuptake transporter (SERT), have been reported in IBS. Despite an 
improved understanding of the enteric nerve system and its involvement in gastrointestinal 
function, further knowledge is essential to understand the pathophysiology of gastrointestinal 
disorders like IBS.
Serotonin (5-hydroxytryptamine; 5-HT) 
Serotonin (5-HT) is a monoamine primarily found in blood platelets, the central nervous 
system and in the digestive tract. As mentioned above, 95 % is located in the digestive tract, 
of which 90 % in the EC cells, where it is synthesized and stored in secretory granules at the 
basal border [66]. The remaining 5 % is located within neurons of the enteric nerve system. 
The pathway for 5-HT synthesis is initiated by conversion of dietary L-tryptophan to 5-
hydroxytryptophan by tryptophan hydroxylase, which is the rate limiting enzyme. 
Subsequently, 5-hydroxytryptophan is decarboxylated into 5-HT by the action of 5-
hydroxytryptophan decarboxylase. Newly synthesised 5-HT is packed into secretory granules 
by the vesicular monoamine transporter 1 (VMAT1), which is specific for 5-HT- producing 
EC cells [67]. Released 5-HT can interact with neurons, both intrinsic and extrinsic sensory 
afferent terminals, immune cells, intestinal enterocytes, mucus cells, and smooth muscle 
receptors to regulate secretion, motility and visceral pain perception  [64,68]. Because of the 
constant migration and turnover of the EC cells, and thus no close contact with nerve endings 
or immune cells, a high secretion rate of 5-HT is necessary, and the specificity of responses to 
this paracrine signal is dependent on the receptors reached by the transmitter [69]. The 5-HT 
receptor family comprises fourteen different receptor sub-types, which are grouped in seven 
families. Except for the 5-HT3 receptor, which belongs to the ligand-gated ion channel family, 
all the receptors are G-protein coupled neurotransmitter receptors [70]. The 5-HT3 and 5-HT4
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receptors are both therapeutic targets; 5-HT3 antagonists alleviate nausea and emesis 
associated with cancer chemotherapy [71,72], and 5-HT4 agonists have shown to be effective 
in treatment of constipation-predominant IBS [73,74].
An important aspect of efficient intercellular signalling is the termination of the signal. The 
action of 5-HT in the gastrointestinal tract is terminated by uptake mediated by SERT, which 
is expressed by most epithelial cells [75]. Inflammation of the intestinal mucosa is associated 
with decrease in the expression of SERT [76,77], which impairs the inactivation of 5-HT. The 
accumulation of synaptic 5-HT will excessively potentiate the actions of 5-HT, affecting 
secretory, motility and sensory functions, which can cause abdominal discomfort, pain, 
bloating, nausea, diarrhoea or constipation; effects that are similar to the abnormalities of 
gastrointestinal function and sensation observed in IBS.
Chromogranin A (CgA)
Chromogranin A (CgA) is a member of the granin family of secretory glycoproteins that are 
found within secretory cells of the enteric endocrine and immune systems. The granins are 
proposed to play several roles in the secretory process, from targeting peptide hormones and 
neurotransmittors in granules intracellularly, to regulate hormone secretion extracellularly. 
CgA is a precursor to a range of peptides with possible regulatory functions [78]. Clinically, 
measurement of serum and tissue content of CgA has become a valuable tool in the diagnosis 
of a variety of neuroendocrine tumors (NETs). Carcinoid tumors, which arise from EC cells, 
represent the most common gastrointestinal NETs, and are characterised by increased release 
of CgA and 5-HT into systemic circulation [79].
Circulating CgA levels have recently been studied in patients with IBS, and both elevated and 
reduced levels of CgA have been reported [80,81]. The inconsistency in the results may 
suggest varied CgA levels in subgroups of IBS, but possible pathophysiological role or 
clinical implication is yet to be elucidated. 
1.5 Methodology for the analysis of 5-HT
Traditionally, determination of 5-HT is carried out by enzyme immunoassays, which are 
considered inexpensive and simple to perform. However, their main disadvantages are the 
lack of specificity for complex biological samples, potential cross-reactivity and consequently 
the liability to overestimate the levels of a determined analyte, especially in cases where 
multiple metabolically related products are present. High performance liquid chromatography
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and LCMS (single or tandem) have been successfully used in the determination of 5-HT in a 
wide variety of biological samples such as diverse tissues [82], brain [83], whole blood [84],
serum [85], plasma [86], urine [87], and intestine [88]. It has been suggested that the use of 
LCMS/MS in the analysis of 5-HT offers advantages in terms of specificity and linear range, 
while permitting simultaneous determination of 5-HT metabolic related products [84]. The 
internal standard (IS) technique is the preferred approach to achieve rapid sample analysis 
efficiency at a minimum cost, as opposed to external standard calibration (a technique also 
used in immunological assays). The ideal IS is a compound that resembles the analyte of 
interest. Unfortunately in the majority of prior studies there is no description regarding the 
strategies behind the selection of an optimal amount of IS, especially in cases where the 
analyte may have a wide span of concentrations. The potential applicability, in the analysis of 
biomedical samples, of a multivariate strategy to estimate an optimal concentration of IS and 
a robust response factor (RF), which does not vary with changes in the analyte and internal 
standard concentrations, has previously been suggested [89].
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2. Aims of the Study 
2.1 Overall aim
The present study was part of a project called the MAI-project (“Matallergi og Intoleranse” 
Norwegian translation), which started in 2001 at Haukeland University Hospital (HUH),
Bergen, Norway. The MAI-project embraced patients who self-attributed their gastrointestinal 
complaints to food hypersensitivity in the absence of organic diseases. The patients went 
through an extensive examination program which involved allergologists, gastroenterologists, 
dieticians and psychiatrists/psychologists. The National Institute of Nutrition and Seafood 
Research (NIFES) collaborated with HUH in this interdisciplinary project. 
The overall aim of the present thesis was to study the potential beneficial effect of seal oil in 
gastrointestinal and non-gastrointestinal complaints and to investigate the possible role of EC
cell markers in subjective food hypersensitivity.
2.2 Aims of the papers
Paper I: To compare the effects of duodenal administration of seal oil with that of soy oil on 
gastric accommodation (single dose experiment) and gastrointestinal complaints (single dose 
and short-term experiment) in patients with subjective food hypersensitivity.
Paper II: To investigate the impact of short-term duodenal administered seal oil on SHC, QoL 
and gastrointestinal complaints in patients with subjective food hypersensitivity.
Paper III: To develop a method for analysing 5-HT in gut lavage fluid by LCMS/MS, by 
using a multivariable approach in modelling the relationship 5-HT/IS to select an optimal 
amount of IS. The selected approach was a multivariable model, to investigate how 
simultaneous changes of 5-HT and IS concentrations could affect the response factor (RF), 
and how the mathematical modelling can contribute to select an optimal amount of IS. 
Paper IV: To investigate the possible role of the EC cell markers 5-HT and CgA in gut lavage 
fluid and blood, respectively, in patients with subjective food hypersensitivity.
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3. Material and Methods 
3.1 Patients 
The patients were referred from general practitioners and specialists to HUH because of 
gastrointestinal complaints suspected to be due to food allergy. The patients underwent a 
standardized clinical examination program by an allergologist, a dietician and a 
gastroenterologist. The extensive examination included detailed medical history, physical 
examination, routine laboratory tests in addition to SPT, measurements of serum total- and 
food-specific IgE levels, and DBPCFC performed by a dietician when indicated. The 
gastroenterological investigations included a gastroscopy with gastric and duodenal biopsy 
taking to exclude Helicobacter pylori infection and celiac disease, respectively, and analysis 
of intestinal permeability and levels of calprotectin in gut lavage fluid to exclude IBD. In 
addition, stool samples were investigated to rule out parasitic infections. Patients with organic 
gastrointestinal disease, which could explain their symptoms, and pregnant or lactating 
women, were not included. Also patients who reported anaphylactic reactions or very strong 
atopic reactions combined with high IgE levels were also excluded from the study. All the 
patients that attended this study were part of the MAI-project.
In paper I, in the single dose experiment, ten female patients with subjective food 
hypersensitivity were included (range 28-82 years, mean age 49 years). Twenty-four patients 
(22 females and 2 males, range 24-80 years, mean age 43 years) were included in the short-
term experiment, and they were randomly allocated to treatment with either seal oil (n = 12; 
11 females and 1 male, mean age 45 years) or soy oil (n = 12; 11 females and 1 male, mean 
age 41 years). 
In paper II, 34 patients with subjective food hypersensitivity were included in the study, but 
only 26 patients completed the seal oil treatment and filled in all four questionnaires 
(Subjective Health Complaints Inventory, short form of the Nepean Dyspepsia Index, 
Gastrointestinal Symptom Rating Scale and Ulcer Esophagitis Subjective Symptoms Scale). 
Of the remaining 26 patients, 23 were female and 3 were male (range 26-88 years, mean age 
47 years). 
25
In paper III, six patient samples were randomly chosen from the MAI-material for the purpose 
of method development for determination of 5-HT in gut lavage fluid using liquid 
chromatography ion-trap tandem mass spectrometry technique.
In paper IV, 69 patients with subjective food hypersensitivity were included (55 females and 
14 males, mean age 39 years, range 21-83 years). Gut lavage fluid was collected in all 69 
patients for determination of 5-HT, and blood samples for analysis of serum CgA were 
obtained from 32 out of 69 patients. 
3.2 Control subjects
The healthy subjects were mainly employees at NIFES and students at the University of 
Bergen. Inquiry and study information were sent by e-mail. Participants that reported having 
regularly gastrointestinal complaints or suspected adverse reactions to foods were not 
included. However, no medical examinations of the recruited healthy subjects were 
performed. In paper I in the single dose experiment, the patients with self-reported food 
hypersensitivity were compared with ten healthy subjects (4 females and 6 males, range 23-56
years, mean age 31 years). 
In paper IV, 34 healthy volunteers (24 females and 10 males, range 23-61 years, mean age 33 
years) were included in the study. Twenty-seven patients admitted to the Section of 
Gastroenterology at HUH because of suspected IBD were also included as a control group (11 
females and 16 males, range 21-65 years, mean age 35 years). 23 out of 27 patients were
diagnosed with IBD (19 had Crohn’s disease and 4 had ulcerative colitis).
Overview of study design, material and methods are given in table 1.
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Table 1. Overview of study designs, material and methods in paper I-IV.
PAPER I PAPER II PAPER III PAPER IV
Experimental 
groups
Singel dose: 10 S-
FH patients
Short-term: 12 S-
FH-patients
26 S-FH patients 6 S-FH patients
(method 
development)
69 S-FH patients
Comparison groups Singel dose: 10
healthy adults
Short-term: 12 S-
FH patients
34 healthy adults
23 IBD patients
Experimental oils Seal oil and soy oil Seal oil
Daily 
dosage/duration of 
oil administration
Single dose: 10 mL
Short-term:
10 mL × 3/10 days
10 mL × 3/10 days
Ultrasonography 2D ultrasound
Symptom 
registration
Visual Analogue 
Scale
Questionnaires SF-NDI, SHC, 
GSRS, UESS
Intestinal lavage 5-HT (method 
development)
5-HT (sample 
quantification)
Blood samples CgA
S-FH=subjective food hypersensitivity; IBD=inflammatory bowel disease; 2D=two dimensional; SF-NDI=Short 
Form of the Nepean Dyspepsia Index; SHC=Subjective Health Complaints; GSRS=Gastrointestinal Symptom 
Rating Scale; UESS=Ulcer Esophagitis Subjective Symptoms Scale
3.3 Methods
3.3.1 Marine and vegetable oils
In paper I and II, refined seal oil (Rieber Skinn A/S, Bergen, Norway) was used. The seal oil 
was from adult harp seal (Phagophilus groenlandicus), and a combination of natural and 
synthetic tocopherols, the latter being dl-Į WRFRSKHU\O DFHWDWH ZHUH DGGHG DFWLQJ DV
antioxidants by scavenging lipid radicals from potentially oxidised PUFAs. To further protect 
the seal oil against oxidation, a top layer of nitrogen was added to the bottles, and stored in a 
refrigerator (kept around 4 °C) GXULQJVWXG\RWKHUZLVHLQí&IUHH]HUThe level of dioxins 
in the seal oil was below the current European Union upper limits in marine oils for human 
consumption (2 pg WHO-TEQ/g fat).
In paper I, the effect of seal oil was compared to commercially available soybean oil (Mills 
DA, Oslo, Norway).  The soybean oil was naturally high in linoleic acid (18:2n-6, LA). See 
Table 2 for an overview of fatty acids, fat soluble vitamins A and E, and lipid peroxidation 
(thiobarbituric acid reactive substances, TBARS) in the seal oil (paper I-II) and soy oil (paper 
I). 
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Table 2. fatty acid profile (g/100 g), vitamins A, D and E and TBARS in
                     experimental oils
Analyte Seal oil Soy oil
14:0           4.5 n.d
16:0 8 9.7
18.0 1.2 3
VDWXUDWHG 14.2 13.4
16:1n-7 14 n.d
18:1n-11 3.2 n.d
18:1n-9 14.9 17.5
18:1n-7 3.8 1.3
20:1n-11 1.6 n.d
20:1n-9 7.7 .2
22:1n-11 1.8 n.d
PRQRHQHV 48.9 19
18:2n-6 1.5 49.7
20:4n-6 .6 n.d
Q-6 2.2 49.7
18:3n-3 .6 5.5
18:4n-3 1.6 n.d
20:4n-3 .5 n.d
20:5n-3 7.9 n.d
22:5n-3 3.7 n.d
22:6n-3 8.6 n.d
Q-3 23.9 5.5
n-6/n-3 .1 9
Sum vitamin A .3 mg/100 g n.d
Vitamin D3 n.a 15 μg/100 g
D-tocopherol 4.5 mg/100 g 17.1 mg/100 g
TBARS 3.6 nmol/g w/w n.d
                       Monoenes = monounsaturated fatty acids. Sum vitamin A = sum retinol (13-, 11-,
                       9-cis and all-trans retinol ie, A1) and 3.4 didehydroall-trans retinol (A2). TBARS = 
                       thiobarbituric acid reactive substances. w/w = wet weight.
3.3.2 Mode of oil administration and oil dosage
In paper I and II, the experimental oils were administered via a nasoduodenal tube (Freka®
Feeding Tube, Fresenius Kabi, GmbH, Germany). By aid of fluoroscopy and a stylet, the 
nasoduodenal tube was positioned with its tip to the middle part of the duodenum. The tube 
was secured with tape to the cheek. This mode of administration was chosen to ensure 
compliance considering the relatively high amount of oil self-administrated by the participants 
during the 10 days’ trial period. On the first trial day, health personnel at the hospital 
demonstrated how to administrate the oils, via the tube, using a syringe. The participants kept 
the nasoduodenal tube inserted during the entire trial period. Below is a fluoroscopy image of 
a nasojejunal feeding tube, located with its tip at the ligament of Treitz (duodenal- and jejuna 
junction) (Figure 2), and not in the middle or distal part of the duodenum, as in the present 
thesis.
The patients with subjective food hypersensitivity in paper I and II received approximately 
6.1 g of EPA+DHA from the 30 mL daily dosage of seal oil. The seal oil also provided a daily 
dosage of approximately 1.1 g of DPA. The dose of seal oil was chosen based on previous 
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studies where the same mode of administration and amount of seal oil was used with 
promising results and no reported harmful effects [90,91].
Figure 2. Fluorscopy image of an inserted nasojejunal feeding tube. With permission from Arnold Berstad.
3.3.3 Two-dimensional ultrasonography
Ultrasonography is established as a clinical method with high applicability in diagnostic and 
prognostic evaluations. Ultrasound is a non-invasive, cheap, radiation-free, user- and patient-
friendly method allowing repeated and prolonged examinations [92]. Transabdominal 
ultrasound is useful in assessing gastric emptying, size, accommodation and contractile 
activity, and thickness of wall and diameter of small and large bowel [54,93,94]. The method 
has limitations when it comes to depth penetration, especially in obesity, and the presence of 
intestinal gas may impair image quality [95].
Scanning procedure
The patients were scanned while sitting in a chair, leaning slightly backward an angle of 120º 
between the thighs and the spine. 2D ultrasound images were obtained using a sector scanner 
(System Five, GE Vingmed Ultrasound, Horten, Norway) with a built in magnetometer-based 
position and orientation measurement (POM) device (Flock of Birds® Model 6D FOB., 
Ascension Technology Corp., Burlington, VT, USA). Each standardized image was frozen 
before being recorded on to videotape and stored on System Five ultrasound scanner. A 
proximal gastric area in a sagittal section was outlined by tracing from the top margin of the 
fundus and 7 cm downward along the axis of the stomach. Within 7 cm along the axis of the 
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outlined sagittal section of the proximal stomach, the maximal diameter was chosen as sagittal 
diameter. The sagittal section of antral area was measured by tracing the outer profile of the 
muscularis propria of the gastric wall. In those cases in which air pockets were present in the 
selected sonographic section, the outer border of the air pocket was traced. The measures 
were traced twice and the average result recorded. Three ultrasonographic measures were 
calculated at each recording time: proximal gastric area, frontal diameter and antral area. To 
assure compliance, all sonographic examinations and measurements were performed by Dr. 
Med. Gülen A. Lied. 
3.3.4 Meal-induced symptoms
In paper I, a commercial meat soup (Toro® clear meat soup, Rieber & Søn A/S, Bergen, 
Norway) was applied for symptom provocation and evaluation of gastric accommodation. At 
each experiment, the subjects drank during 4 min 500 mL of the soup containing 1.8 g 
protein, 0.9 g bovine fat, 1.1 g carbohydrate and 0.2 g non-soluble seasoning (20 kcal totally). 
The soup was boiled and then cooled to 37 ºC before ingestion. In previous studies this soup 
meal induced fed state motility with approximately 3 antral contractions per min in over 85 % 
of patients and controls [93].
The participants were asked to score the meal-induced symptoms (epigastric pain, nausea, 
fullness, satiety and discomfort) on a 100 millimetre visual analogue scale (VAS), where zero 
denotes absence of symptoms and 100 denotes excruciating symptoms. This Norwegian 
version of VAS has previously been validated in terms of reliability, validity and sensitivity 
[96,97].
3.3.5 Questionnaires
Short Form Nepean Dyspepsia Index (SF-NDI)
The SF-NDI is a 10-item questionnaire with five subscales measuring the influence of 
dyspepsia on domains of health related QoL, namely tension, interference with daily 
activities, altered eating/drinking habits, knowledge/control over disease symptoms and
interference with work/study, and each subscale contains two items. The scores were 
determined by measuring each item by a five-point graded Likert scale ranging from 1 (not at 
all or not applicable), 2 (a little), 3 (moderately), 4 (quite a lot) to 5 (extremely). The total sum 
score for QoL ranges from 10 to 50, and the sum score of each of the five subscales ranges 
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from 2 to 10. Higher scores indicate poorer QoL. The 10-item SF-NDI has been validated in 
patients with functional dyspepsia [98], as well as in patients with subjective food 
hypersensitivity [26].
Subjective Health Complaint (SHC) Inventory
The SHC Inventory includes 29 items concerning subjective, somatic and psychological 
complaints. The questionnaire contains five subscales: musculoskeletal pains (migraine, 
headache, arm pain, shoulder pain, neck pain, upper back pain, lower back pain and leg pain), 
gastrointestinal problems (gas discomfort, stomach discomfort, gastric ulcer, heartburn,
diarrhoea, constipation and stomach pain), allergy (allergies, breathing difficulties, eczema 
and asthma), “pseudoneurology” (tiredness, sleep problems, dizziness, heath flushes, extra 
heartbeats, sadness/depression and anxiety) and flu (cold/flu and coughing). The scores were 
determined by rating each item by a four-point graded Likert scale ranging from 0 (not at all), 
1 (a little), 2 (quite a lot) to 3 (severely). 
Gastrointestinal Symptom Rating Scale (GSRS)
The questionnaire includes 15 items which are grouped into five subscales: abdominal pain 
syndrome (abdominal pain/discomfort, sucking sensation in the epigastrium, nausea and 
vomiting), reflux syndrome (heartburn and acidic regurgitation), indigestion (borborygmi, 
abdominal distension, eructation and increased flatus), diarrhoea (increased passage of stools, 
loose stools and urgent need for defecation) and constipation (decreased passage of stools, 
hard stools and feeling of incomplete evacuation). The scores were determined by rating each 
item by a 7-point graded Likert scale, and higher scores indicate more pronounced symptoms. 
Ulcer Esophagitis Subjective Symptoms Scale (UESS) 
The UESS was developed to examine the symptoms frequently experienced by patients with 
peptic ulcer and esophagitis. The questionnaire includes 9 items which are grouped into four 
subscales: abdominal discomfort (abdominal pain, sucking sensation), reflux discomfort (acid 
regurgitation, heartburn), intestinal discomfort (abdominal distension, borborygmi) and sleep 
dysfunction (difficulty falling asleep, insomnia and rested waking up). The scores were 
determined by rating each item by a 100 mm VAS, and higher scores indicate more 
pronounced symptoms.
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3.3.6 Intestinal lavage
Intestinal lavage was performed to collect gut lavage fluid (paper III and IV) (Figure 3). The 
method is briefly described as following: by aid of a gastroscope, a nasoduodenal tube 
(Freka® Feeding Tube, Fresenius Kabi, GmbH, Germany) was positioned with its tip to the 
distal part of the duodenum. Two litres of isotonic polyethylene glycol solution (PEG, MW 
3350, Laxabon£, Tika, Sweden) was administered through the nasoduodenal tube during 40 
minutes using a peristaltic pump (Watson Marlow 505S/RL, Falmouth, England). The first 
clear fluid passed per rectum was collected and filtered through gauze, and a 4 mL aliquot 
was collected on tubes containing 0.5 mL of a solution with antiseptic and antiproteolytic 
activity prepared by adding 1 ml of 10% sodium azide (NaN3) to 50 ml of soybean trypsin
inhibitor (Sigma, Taufkirchen, Germany). The samples were stored at -80 °C prior to analysis.
Figure 3. Illustration of the intestinal lavage procedure. Illustration by Jørgen Valeur.
3.3.7 Laboratory analysis
Gut lavage fluid was collected from patients with subjective food hypersensitivity (paper 
III-IV), patients with IBD and healthy controls (paper IV), according to procedure 
previously described [99], for analysis of 5-HT. The gut lavage fluid specimens were 
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thawed and centrifugated at 3000 rpm for 10 minutes at 4 ºC. The supernatant was collected 
and filtered by using a hydrophilic nylon membrane syringe filter, 4 mm diameter and 0.45
ȝP SRUH VL]H &KURPDFRO /WG 7UXPEXOO 86$ $OLTXRWV RI  ȝO RI WKH ILOWHUHG
supernatants were transferred into tubes containing internal standard (5-
methoxytryptamine; 5-CH3O-HT, Cat. No. 286583, Sigma-Aldrich Co), evaporated to 
dryness in advance. The tubes were vortex-mixed for 1 min, transferred to an autosampler 
vial and submitted to LCMS/MS for analysis of 5-HT. The sample preparation is 
schematically outlined in Figure 4.
Figure 4. Schematic demonstration of sample preparation of gut lavage fluid.The samples were thawed and 
centrifugated, and the supernatant was collected and filtered by using a syringe filter, 0.45 ȝm pore size. 
Aliquots of 50 ȝl were added to test tubes containing IS, and after being vortexed,  submitted to LCMS2
analysis.  Illustration by the author.
Fasting venous blood samples were collected from patients with subjective food 
hypersensitivity and healthy controls (paper IV) using vials with no added anticoagulants 
(gel vials), for the analysis of serum CgA. The blood samples were centrifugated and stored 
at -80 °C prior to analysis. Serum CgA was measured by enzyme-linked immunosorbent 
assay (ELISA), following the manufacturer’s instructions (ALPCO Diagnostics, Salem, 
N.H., USA; cat. #43-CHRHU-EO 1.2).
The methyl ester fatty acid (FA) composition of total lipids in seal oil (paper I-II) 
and soy oil (paper I) were determined by gas liquid chromatography (GLC) at NIFES as 
described previously [100], with some modifications. In brief, total lipid content was 
extracted, filtered and evaporated, and thereafter the samples were saponified and the FAs
were esterified in 20 % boron fluoride in methanol, and biological sample parallels were 
analysed. The methyl esters were separated using a gas chromatograph (Trace GC 2000), 
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equipped with a 50 m CP sil 88 (Chrompack) fused silicia capillary column (id: 0,32 mm), 
using “cold on column” injection, with a temperature programme of 6025qC/min
16025qC/min 19025qC/min 220qC5min and flame ionization detector. The FA profiles were
calculated using an integrator (Turbochrome Navigator, Version 6.1), connected to the 
GLC instrument and identification ascertained by standard mixtures of methyl esters (Nu-
Chek, Elyian, USA). The nonadecanoic acid (19:0) methyl ester was used as IS for 
quantification of FA methyl esters. Limit of quantification (LOQ) was 10 Pg FA/g sample 
(wet weight, w/w). 
TBARS were analysed in both seal oil (paper I-II) and soy oil (paper I) at NIFES by 
a modified in vitro method, measuring mainly malondialdehyde and other aldehydes, and 
secondary lipid peroxidation parameters [101,102]. Briefly, fat and water-soluble 
components are separated, while the analytes are being extracted in a methanol:water 
phase. An aliquot of the extract is added thiobarbituric acid (TBA) in excess and heated to 
form a coloured complex between aldehydes in the sample and TBA. The absorption at 532
nm was registered and TBARS were quantified by reference to an external standard curve 
in a spectrophotometer. LOQ was 3,9 nmol TBARS/g sample (w/w).
Vitamin A, i.e. sum retinol (13-, 11-, 9-cis and all-trans retinol, i.e. A1) and 3,4 
didehydro-all-trans retinol (A2), were analysed in seal oil (paper I-II) and soy oil (I) at 
NIFES by a modified high performance liquid chromatography (HPLC) method [103,104].
In brief, the sample is saponified, while the unsaponified material is extracted, and analysed
by a HPLC column (HICHROM 4,6 × 150 mm, LC-SI, 3 Pm, Teknolab A/S) using an ultra 
violet (UV)-detector (Thermo Separations products, UV1000, Intrument-teknikk AS), with 
reference to an external standard curve. LOQ in oils was 280 ng vitamin A1/g sample and 
460 ng vitamin A2/g sample, both w/w. 
Vitamin E was analysed in seal oil used in paper I and II. The analysis was 
performed at NIFES by HPLC, based on the principles reported by the European 
Committee for Standardization (CEN) [105]. Briefly, the sample is saponified, while the 
unsaponified material is extracted. Alpha-, beta-, gamma- and delta-tocopherol isomers 
were determined using a HPLC column (LiChroART, 4,6 × 125 mm, Purospher STAR Si, 
3 Pm, Merck) equipped with a fluorescence detector (TSP, FL3000, Spectra system) and 
quantified by DQ H[WHUQDO VWDQGDUG FXUYH ,Q WKH SUHVHQW VWXG\ RQO\ Į-tocopherol was 
UHSRUWHG/24LQRLOVZDVQJĮ-tocopherol/g sample (w/w).
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Vitamin D was analysed in soy oil at NIFES by HPLC as described earlier. Briefly, 
sample material is saponified and the unsaponified material is extracted before clean-up on 
a preparative column (HICHROM, Kromasil silicia, 5 μm, 4.6 x 250 mm). The fractions 
with vitamin D2 (ergocalciferol) and D3 (cholecalciferol) are collected, evaporated and 
dissolved in methanol, before injected on an analytical reverse phase column (Ace 5 C18, 5
μm, 4.6 × 250 mm). Vitamin D3 was determined by UV-detector (LaChrom, Merck 
HITACHI L-7420) and quantified using vitamin D2 as IS. LOQ was 1 μg vitamin D3/100 g 
sample (w/w).
3.3.8 Liquid chromatography tandem mass spectrometry
A Liquid chromatography tandem mass spectrometry (LCMS/MS) system was used for 
method development (paper III) and analysis and quantification of 5-HT in gut lavage fluid 
(paper IV).  The LCMS/MS used in the present study was an Agilent 1100 series LC/MSD 
trap, SL model with an electrospray interface (ESI), a quaternary pump, degasser, 
autosampler, thermostatted column compartment, variable-wavelength UV detector and 25
Pl injection volume. The column, a Zorbax Eclipse-C8 RP 150 × 4.6 mm, 5 Pm (Agilent 
Technologies. Palo Alto, CA, USA) is a double endcapped column 100 % water compatible 
which can be operated at maximum pH range of 2-9 and provides improved basic peaks of
amines compounds (such as 5-HT) due to the polar groups embedded in the stationary 
phase. The column was kept in the column compartment at 20 °C and the solvent system in 
gradient mode consisted of water with formic acid 0.1 % v/v (A) and acetonitrile (B) and 
UV detection at 254 nm and 0.2 mL/min flow rate. The initial condition 100 % of A was 
ramped to 35 % of A in  20 min, returned immediately to 100 % of A in 5 min and held 
there for 5 min. Nitrogen was used as nebulizing and drying gas at 300 °C. The ESI source 
was operated in positive ion mode and the ion optics responsible for getting the ions in the 
ion-trap such as capillary exit, skimmer, lens and octapoles voltages were controlled by 
using the Smart View option with a resolution of 13000 m/z/sec (FWHM/m/z = 0.6-0.7). 
Complete system control, data acquisition and processing were done using the ChemStation 
for LC/MSD version 4.2 from Agilent. 7KHWUDQVLWLRQVPRQLWRUHGZHUHĺm/z for 
5-+7DQGĺm/z for IS, 5-methoxytryptamine (IS). The magnitude of the signals 
was recorded in ion counts per second (icps). A representative ion chromatogram of a gut 
lavage fluid sample is shown in Figure 5.
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Figure 5. A) Representative ion chromatogram of one of the GLF sample. B) Extracted ion chromatograms at 
160 and 174 m/z obtained by fragmenting [5-HT+H]+ and [5-CH3O-HT+H]+ signals 177 and 191 m/z
respectively. C and D) MS/MS product ion spectra for 177 and 191 m/z, respectively. Figure processed by 
ChemStation for LC/MSD version 4.2, Agilent.
3.3.9 Selection of optimal amount of 5-CH3O-HT
A uniform shell design proposed by Doehlert [106] was applied to model the relationship 
between 5-HT and 5-CH3O-HT, in terms of linearity of the detector response (paper III). The 
main characteristics of this design are:
x The number of experiments is calculated by the general expression X2 + X + 1 where
X represents the number of variables studied. For instance, to investigate the effect of 
two variables (X = 2) seven experiments will be required. 
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x The experiments are allocated at the centre and at the vertexes of a hexagonal shape, 
circumscribed in a circle of radius 1, in this way the variances of the estimated 
responses are the same at all points on the circle centred at the origin.
x The variables are codified and equally spaced between -1 and 1 and by using basic 
geometric it is possible to determine the coded combination of the variables at each 
vertex of the hexagon. Figure 1 in paper III described how the coded levels of the 
variable x1 (represented by question marks) are calculated by using Pythagoras’
theorem.
x The variables are simultaneously investigated at different numbers of levels. Figure 1 
in paper III shows how the coded variables x1 and x2 are studied at 3 and 5 levels (-
0.866, 0, 0.866 and -1, -0.5, 0, 0.5, 1), respectively. The coded levels are then
converted into ȝg/mL values.
The application of this design in the determination of the optimal amount of IS to be used in 
the quantitative determination of 5-HT was as follows:
Test tubes containing seven different concentration ratios of 5-HT:IS LQȝl of ethanol
were prepared in triplicates (7 × 3 = 21 tubes) and evaporated to dryness under a stream of 
nitrogen at room temperature. A gut lavage sample with no detectable levels of 5-HT was 
thawed at room temperature, and prepared as described above $OLTXRWV RI  ȝl of the 
filtered supernatant were added into the aforementioned 21 test tubes. The tubes were 
vortex-mixed for 1 min, transferred to an autosampler vial and submitted to LCMS/MS 
analysis. A GLF blank sample spiked with 3 μg/mL of 5-HT and 16 μg/mL of IS was 
prepared in triplicate to check the prediction capability of the model to be proposed. The 
analytical signals recorded with this additional solution along with those obtained by 
applying the uniform shell design, were used for modelling purposes. 
3.4 Statistics
All statistical calculations and graphic designs were performed using the GraphPad Prism 
statistical software package (GraphPad Prism version 4.00 and 5.00 for Windows, GraphPad 
Software, San Diego, USA). In general, results are given as means with standard deviations or 
standard errors, as indicated. Differences between means were evaluated by t-tests or 
ANOVA, and between proportions by chi square tests. Regression analysis in paper III was 
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done by Statgraphics Plus 5.1 software package (Statistical Graphics Corp., Herndon, USA).
3.5 Ethics
The study trials were performed according to the Declaration of Helsinki, after approval from 
the Regional Committee for Medical Research Ethics and written informed consent from 
patients and controls. The collection of the gut lavage fluid from the patients was part of the 
routine examination, and the samples were stored in an approved biobank at HUH prior to 
analysis. When analysed, the gut lavage fluid samples were stored in an approved biobank at 
NIFES (paper III). The gut lavage fluid samples obtained from patients and used during 
method development in paper IV were approved for research. The blood samples obtained 
from patients and controls in paper IV were stored in an approved biobank at HUH. 
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4. Summary of results 
4.1 Paper I
Effects of seal oil on meal-induced symptoms and gastric accommodation in patients 
with subjective food hypersensitivity: a pilot study
In the single dose experiment, 10 patients and 10 healthy volunteers received 10 mL duodenal 
administered seal oil or soy oil. The gastric accommodation of the proximal and distal 
stomach, examined by 2D ultrasonographic scanning, and meal-induced abdominal 
symptoms, assessed by VAS, were not significantly influenced by single doses of seal or soy 
oil. 
In the short-term treatment study, 24 patients were randomly allocated to 10 days’ treatment 
with either 10 mL of seal or soy oil, self-administrated through a nasoduodenal feeding tube, 
3 times daily. Seal oil, but not soy oil, reduced total symptom score significantly (p = 0.03). 
However, the symptomatic improvement was not associated with improvements in gastric 
accommodation.
4.2 Paper II
Seal oil in patients with subjective food hypersensitivity: An open explorative pilot study
Twenty-six patients received 10-day open treatment with seal oil, 10 mL self-administrated 
three times daily. Before and after treatment, and 1 month post-treatment, patients filled in the
SHC Inventory for non-gastrointestinal symptoms in addition to the SF-NDI for evaluation of 
QoL, the UESS score and the GSRS for gastrointestinal symptoms. Total sum score of the 
SHC Inventory was significantly reduced between before and after 10 days’ seal oil treatment 
(p < 0.0001), and between before and 30 days after ended seal oil treatment (p = 0.0008). 
Total sum score of the SF-NDI was significantly reduced from baseline both at 10 days (p <
0.0001) and at 30 days post-treatment (p = 0.0008). The decrease from baseline for the total 
sum score of the GSRS and the UESS, were significant at 10 days, p = 0.007 and p < 0.0001, 
respectively, and at 30 days post-treatment, p = 0.02 and p = 0.0006, respectively. Thus, both 
non-gastrointestinal and gastrointestinal complaints were significantly improved from 
baseline both at 10 and 30 days post-treatment.
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4.3 Paper III
Direct determination of serotonin in gut lavage fluid by liquid chromatographic ion trap 
tandem mass spectrometry
A new method for direct determination of serotonin in gut lavage fluid was established. The 
method involves addition of 5-methoxytryptamine (5-CH3O-HT) IS, centrifugation, filtration 
and injection of the sample supernatant in a liquid chromatographic system coupled to an ion-
trap tandem mass detector. Electrospray in positive mode was used to isolate and fragment the 
protonated ions [5-HT+H]+ and [5-CH3O-HT+H]+ signals 177 and 191 m/z respectively.
Different response factor values were estimated by using a multivariate model, suggesting that 
the interaction 5-HT/IS is an important factor that affects the validity of the RF and 
consequently the accuracy of 5-HT determination. The systematic and simultaneous 
experimental design applied on the entire 5-HT concentration range (2 – 12 μg/mL), resulted 
in a constant RF of 0.040 and a IS concentration of 2 μg/mL to perform a reliable 5-HT 
quantification. 
4.4 Paper IV
Subjective food hypersensitivity: assessment of enterochromaffin cell markers in gut 
and blood
Analysis of 5-HT was performed in gut lavage fluid from patients with subjective food 
hypersensitivity (n = 67), patients with IBD (n = 23) and healthy controls (n = 17). Blood 
samples for CgA analysis were obtained from 30 patients with subjective food 
hypersensitivity and 34 healthy volunteers. Serum levels of CgA were significantly lower in 
patients with subjective food hypersensitivity compared to healthy controls (p = 0.04). No 
significant difference in gut lavage 5-HT was detected between patients with subjective food 
hypersensitivity, patients with IBD and healthy controls.
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5. General discussion 
5.1 Patients
The patients in the present study attributed their gastrointestinal complaints to the ingestion of 
food, and many believed to suffer from food allergy or non-allergic food hypersensitivity. 
However, immune-mediated food allergy was not detected, and only occasional cases of non-
allergic food hypersensitivity could be verified. The high discrepancy between perceived food 
hypersensitivity and confirmed food allergy, by current available diagnostic methods, is in 
accordance with findings in previous studies [26,33]. Despite extensive medical work-up, the 
patients’ gastrointestinal complaints remained unexplained, and we therefore denoted the 
patients’ condition as ‘subjective food hypersensitivity’ in the present thesis. The patients’ 
gastrointestinal complaints complied with a FGID; in fact, as many as 90 % of the patients 
who participated in our studies have IBS, and some few FD, according to Rome II criteria. 
In addition to gastrointestinal complaints, the patients with subjective food hypersensitivity 
also reported multiple non-gastrointestinal complaints, like musculoskeletal complaints, 
fatigue and sleep disorders, and also psychological problems like anxiety and depression were 
frequently reported. This co-morbidity of gastrointestinal and non-gastrointestinal complaints 
emphasizes the complex nature of this patient group. The existence of subgroups seems very 
likely, but to designate the patients to defined groups will be challenging due to a 
comprehensive and multifactorial symptomatology.       
There was a clear predominance of women in the present study (over 90 %). This gender 
difference is consistent with other studies on patients with subjective food hypersensitivity 
[26,27]. In general, the prevalence of FGID, mainly IBS, seems to be higher in women, at 
least of those who seek health care services [107,108]. There is evidence to support a gender-
related difference in pathophysiology and management of FGID [109], however, it is 
unknown whether the differences are disease-specific, or more a reflection of general gender 
differences. 
5.2 Oil administration and dosage
In the present thesis, the seal oil was administered via a nasoduodenal tube (paper I and II). 
Although installation is an invasive and cumbersome procedure, the treatment was 
remarkably well tolerated and largely without side-effects in patients with subjective food 
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hypersensitivity, and the mode of administration secured nearly perfect compliance 
(according to the patients’ verbal reports). The targeting delivery into the small intestine may 
also reduce potential gastroesophageal reflux, nausea and vomiting [110].
The therapeutic benefit observed following this short-term strategy suggests that a rapid 
booster effect may be achieved by duodenal administration of seal oil [90,91,111,112,113].
No direct comparative study of oral versus duodenal administration of marine oils for pain 
relief exists, but it is worth noticing that 14 days’ orally administrated seal oil showed no 
significant effect in patients with IBD or psoriatic arthritis [114,115]. The fact that EPA and 
DHA most likely represent the main bioactive component of marine oils [116], has lead to an 
increased use of highly purified LC n-3 PUFA capsules, e.g. free fatty acids or ethyl esters. 
Capsules may be a good alternative in long-term trials, especially when it comes to blinding. 
Interestingly, capsules containing free LC n-3 PUFA were not effective in patients with 
Crohn’s disease [117].
In the present study (paper I + II) natural triacylglycerol (TAG) oil was used, and the 
daily dosage of 30 mL provided a relative high dose of EPA + DHA (6.1 g/day), in addition to 
1.1 g/day DPA. A dosage of 2.7 g/day EPA + DHA gave a moderately anti-inflammatory 
effect in long-term treatment of rheumatoid arthritis [118]. Thus, 6.1 g/day of n-3 LCPUFAs 
was considered to be a proper dose in the present study. Duodenal lipid infusion has been 
reported to exacerbate symptoms in patients with FGID, like FD [119,120], but the duodenal 
infused seal oil in the present study did not reproduce or worsen the patients’ symptoms. On
the contrary, the patients experienced attenuation of their symptoms.
5.3 Effect of seal oil on gastrointestinal complaints
Gastrointestinal complaints constitute a large part of the symptomatology in subjective food 
hypersensitivity. The patients’ gastrointestinal complaints usually manifest after ingestion of a 
meal, with emphasis on abdominal pain/discomfort, nausea, diarrhea and sensation of being 
bloated and full. Following a 10-day intraduodenal administration of seal oil in the present 
study, gastrointestinal complaints were significantly attenuated (paper I and paper II). The 
mechanisms of action may be due to the anti-inflammatory and immune-modulating 
properties of the long chain n-3 PUFAs. The anti-inflammatory effect is supposed to be 
brought about by modulation of the amount and types of eicosanoids produced via the COX 
and LOX enzyme pathways. Consistently, plasma levels of pro-inflammatory PGE2 was 
reduced in response to 10 days’ treatment with duodenal administered seal oil in patients with 
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IBD-related joint pain [112]. Unfortunately, the present study did not include analysis of 
PGE2, due to logistical problems on the lab. However, we conducted a small trial where four 
patients with subjective food hypersensitivity ingested 20 mL seal oil per day for four weeks, 
and PGE2 analysis by LCMS/MS was performed (results not published, Figure 6). The 
protocol applied for the analysis of PGE2 was developed at NIFES [121]. Interestingly, we 
found that PGE2 level in plasma decreased following four week per-oral seal oil treatment 
(Figure 6). Although this result is based on only 4 patient samples, it indicates that an effect is 
measurable after short-term seal oil treatment. Placebo effects are considered to be strong in 
patients with subjective food hypersensitivity [122,123], but taken together with the findings 
noted above [112], it is reasonable to say that the positive effects of short-term seal oil 
treatment reported in the present thesis cannot solely be ascribed a placebo effect. The fact 
that 10 days’ duodenal soy oil treatment did not have any effect on meal-induced
gastrointestinal symptoms (paper I), supports the possibility that the positive effect is 
conserved for seal oil due to its contribution of n-3 LC-PUFAs which interrupt specific 
receptor-mediated signaling pathways involved in pain perception. By virtue of its high 
content of n-6 LA, soy oil will induce PGE2 production, while the n-3 LCPUFAs, especially 
EPA, from seal oil will act inhibitory. 
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Figure 6: Plasma PGE2 level (ng/mL) measured in patients with subjective food hypersensitivity before and after 
ingestion of seal oil (20 mL/day for 4 weeks). Data are given as individual values. P-value = 0.09.
In general, increased levels of PGE2 mediate typical aspects of inflammation, including pain, 
edema and fever. PGE2 is found to play a direct role in pain perception through interactions 
with the EP1 receptor [124]. Low-grade inflammation of the intestinal mucosa has been 
proposed to play an important role of the etiology in IBS [43]. Spiller et al., found increased 
number of inflammatory cells in the colonic and ileal mucosa of IBS patients [125], and
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recently, significant elevated levels of PGE2 and LTB4 in patients with IBS were reported 
[126]. These findings support a mild activation of the immune system, in at least a subset of 
IBS patients. It is also interesting the findings of Lillestøl and colleagues, who reported 
increased intestinal permeability and increased duodenal IgE-bearing mast cells, which 
significantly correlated with serum total IgE levels, in patients with subjective food 
hypersensitivity [127]. In addition, Arslan Lied and colleagues, recently reported increased 
concentrations of B-cell activating factor (BAFF) in blood and in gut lavage fluid, and 
increased serum CD38 levels, which are released from monocyte-derived dendritic cells 
[128]. Hence, all findings regarding increased number of “IgE-armed” mast cells, BAFF and 
dendritic cells support the notion of immune activation in patients with subjective food 
hypersensitivity [129].
The visceral sensory system may be sensitized by inflammation, leading to lowered 
threshold to stimuli, which may lead to intestinal motor abnormalities and abdominal pain and 
discomfort, which are reported by a large proportion of patients with IBS. Especially, there 
are indications that patients with PI-IBS are good candidates for developing low grade 
mucosal inflammation [130]. Even though the clinical relevance needs to be further explored, 
these interesting findings indicate an up-regulated COX and LOX activity, and also that the 
fatty acid profile may be critical to the symptom generation in IBS. NSAIDs are known 
effective drugs in inflammation and pain management, but the analgesic agents are associated 
with troublesome side-effects. The n-3 LCPUFA found in seal oil, and also fish oil and fatty 
fish, act as natural inhibitors and modulators of both the COX and LOX pathways, thus they 
have the potential to modify pathology in diverse inflammatory conditions, free of adverse
side-effects [118].
Visceral hypersensitivity is considered a hallmark of the pathogenesis of FGID, and the term 
refers to an increased sensation of stimuli originating from the abdomen, and both central and 
peripheral sensitization may be important factors. Central sensitization is believed to be due to 
an increase in the excitability of central neurons, so that normal sensory input from the bowel 
is manifested as abnormal peripheral responses. Such change in central processing has been 
suggested to be involved in IBS [108]. The mechanisms of visceral hypersensitivity are not 
fully understood, but both stress and inflammation are believed to be implicated in the 
triggering of pain and discomfort observed in FGID, like IBS, possibly through vagal afferent 
nerve activity. PGE2, a potent mediator during inflammatory response, is believed to act as a 
sensitizer especially in pain sensation. The vagus nerve is an important communicator of the 
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brain-gut interaction, and is increasingly recognised to be involved in control of immune
responses. Dietary fat can affect the vagus nerve by inducing release of cholecystokinin 
(CCK) that binds to CCK-receptors located centrally or on peripheral vagal afferents. 
Activation of CCK-receptors triggers vagal efferents which lead to an increase of 
acetylcholine, which by binding to appropriate receptors, inhibit release of pro-inflammatory 
cytokines like TNF-ĮDQG,/-6 from immune activated macrophages. Based on these findings, 
high fat enteral nutrition has been suggested as potentially therapeutic in various 
inflammatory disorders [131].
In the present thesis, the patients reported discomfort in response to ingestion of 500 mL of
dilute meat soup, suggesting visceral hypersensitivity to be part of the pathophysiology in 
patients with subjective food hypersensitivity (paper I). It may also indicate that the patients’ 
perception of being food hypersensitive might be less specific for particular food items than 
often self-reported. Impaired gastric accommodation has been suspected to cause sensation of 
gastric pain, fullness and early satiety in patients with subjective food hypersensitivity. 
Considering the bolus dosage of 10 mL duodenal administered seal oil in the present study, 
we anticipated that the symptom improvement reported by the patients would be associated 
with improvements in gastric accommodation, due to the effect of LC-PUFAs, through 
increased CCK secretion, on gastric tone. On the contrary, no such improvements in either 
proximal or distal (antral) gastric accommodation, assessed by 2D ultrasonographic scanning,
were observed. Thus, impaired gastric accommodation most likely plays a limited role of the 
aetiology in subjective food hypersensitivity. The gastrointestinal discomfort reported by the 
patients following the test meal, and the consecutive symptom attenuation after short-term 
treatment with seal oil (paper I) may suggest visceral chemosensitivity rather than visceral 
hypersensitivity to mechanical distension, which is characteristic in FD. In a study using a 
post-inflammatory mouse model, altered chemosensitive responses was found, suggesting 
vagal chemosensitive afferents to play a central role in post-inflammatory visceral 
hypersensitivity, like PI-IBS [132]. Whether visceral chemosensitivity mechanisms are 
present in subjective food hypersensitivity, at least in a subset of the patients, warrants further 
investigation. 
In paper II, we found that baseline, or customary, gastrointestinal complaints were 
significantly improved following 10 days’ seal oil administration, as assessed by the GSRS 
and the UESS questionnaires. Interestingly, the patients consistently reported improvement of 
gastrointestinal complaints at 30 days post-treatment compared to baseline as well. A major 
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limitation of this pilot study is the lack of control, and the possibility of placebo effect is 
highly present. However, as seal oil previously improved gastrointestinal complaints in this 
patient group compared to soy oil (paper I), we wanted to first perform an open pilot study to 
examine if positive effects in non-gastrointestinal complaints could be anticipated (discussed 
below). The apparent beneficial effect of short-term duodenal seal oil administration on 
gastrointestinal complaints reported by the patients in paper I and paper II, may be brought 
about by the n-3 LC-PUFAs inhibitory effects of the COX and LOX systems. Especially 
considering the findings reported by Lillestøl et al. [127] and Arslan Lied et al. [133] which 
indicate immune activation in patients with subjective food hypersensitivity, it is likely that 
inhibition of COX activity and subsequently reduction in PGE2 can attenuate pain sensation. 
Another effect of the n-3 fatty acids may be via increased release of CCK, which may reduce 
immune response via actions on peripheral vagal afferents. Indeed, LC fatty acids have been 
found to be a more potent stimulus to CCK secretion,  compared to medium-chain fatty acids 
[119]. The fact that the attenuation of the patients’ complaints was maintained 30 days post-
treatment, could indicate that the effect cannot be assigned exclusively to a placebo effect.
But further controlled studies are highly warranted for confirmation of results.  
Functional alterations of the gut flora, so-called dysbiosis, has recently been suggested as a
key pathogenetic mechanism of several conditions, both extra-intestinal, such as metabolic 
syndrome, allergy and autism, and intestinal, like IBD and IBS [134,135]. Early life stress 
results in an altered brain-gut axis, as shown in a mouse model, suggesting this as a valuable 
model for investigating stress-related disorders including depression and IBS [136]. In man, 
enteric infections, antibiotic usage, and stress may disturb the indigenous gut flora and 
predispose to IBS [137]. Bloating and perception of increased gas production are indeed 
common in subjective food hypersensitivity and IBS, and the complaints most often arises 
after eating. Small intestinal bacterial overgrowth (SIBO) may explain the pronounced 
bloating, due to increased hydrogen excretion. In addition to bloating and distension, visceral 
hypersensitivity, motility disturbances, autonomic dysfunctions and immune activation are 
frequently observed in IBS, and may be understood as a consequence of the host response to 
SIBO [138]. Indeed, Pimentel et al., showed that eradication of bacterial overgrowth 
considerably reduced IBS symptoms [139]. Elimination of the hydrogen produced during 
bacterial fermentation depends primarily on methanogenic and sulphate-reducing bacteria that 
convert hydrogen to methane or hydrogen sulphide [140]. Intriguingly, EPA capsules for 
seven days have been found to reduce total breath hydrogen excretion after challenge with 
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lactitol, another unabsorbable but fermentable carbohydrate [141]. EPA contains five double 
bonds which potentially can be saturated during bacteria metabolism, and thus offer a salvage 
route for excess hydrogen [141]. Whether tube-administered seal oil, rich in EPA, could 
influence microbial metabolism is yet not known. The n-3 PUFA has been found to promote 
adhesion of gut bacteria to mucosal surface, which is pivotal for the beneficial effects of 
probiotics. Indeed, administration of PUFAs increased the number of Lactobacillus paracasei
adhering to jejunal mucosa [142]. Also, a recently study found lower content of lactobacillus 
in n-3 depleted mice compared to mice given an n-3 rich diet [143]. Thus, PUFAs have been 
suggested to enhance the effectiveness of probiotics. 
In SIBO, colonic bacteria will arise in the small intestine and exert its actions there. In 
contrast to methanogenesis, which produce non-toxic CH4, dissimilatory sulphate reduction 
produces highly toxic H2S. SRB utilize several fermentation products, butyrate being one of 
the main substrates. Butyrate is also a major factor to maintain a healthy and functioning 
epithelium barrier, protecting the intestinal mucosa against inflammation and cancer [144].
Indeed, the mucosa itself contains highly sulphated mucins that serve as substrate for SRB. 
These actions of SRB may compromise intestinal barrier function, and increase intestinal 
permeability which may cause hypersensitive responses to foods, and also to bacterial 
endotoxins, like lipopolysaccharide (LPS). Interestingly, increased intestinal permeability has 
been reported in patients with subjective food hypersensitivity [127], but this needs to be 
further investigated to elucidate possible pathogenic mechanisms. 
In the present study, the bolus dosage of 10 mL duodenal administered seal oil, may act as a 
protective layer floating on-top of the mucosa, in the same way as hydrophobic phospholipids. 
This shielding effect is considered an important mechanism in mucosal defence [145].
The role of dietary constituents in FGID is unclear, and a causal relationship between onset of 
symptoms and ingestion of particular food items is often not unambiguously confirmed. But 
considering the high proportion of patients who attribute their complaints to foods, dietary 
factor is most likely implicated in the symptomatology. Milk, bread, cereals and fruits are 
most often recognized as the culprits. Indeed, many patients experience relief of symptoms 
when excluding the suspected food item from their diet. In a recent study, Biesiekierski et al. 
showed that gluten can provoke IBS symptoms in subjects without celiac disease [146] .
Previously, we have shown that ingestion of lactulose, an unabsorbable, but fermentable 
carbohydrate, may replicate the gastrointestinal symptoms in patients with subjective food 
hypersensitivity [45], and Gibson et al., found a number of poorly absorbed short-chain 
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carbohydrates to trigger IBS-like symptoms [46]. Thus, a low FODMAP diet may be effective
in patients with IBS. FODMAPs do not represent the underlying cause to a functional 
disorder, but it constitutes an opportunity for reducing symptoms. It is important to remember 
that ingestion of FODMAPs is normal and tolerated by most people, and that symptoms will 
be generated only when underlying bowel response is exaggerated or abnormal [46].
Several recent observations suggest a component of malabsorption in patients with IBS. Thus 
Morken et al. and Berstad et al., found increased faecal fat excretion in around one forth of 
patients with IBS and food hypersensitivity [147,148]. Consistently, Solakivi et al., found 
decreased levels of PUFA in blood in patients with IBS and suggested that intestinal 
malabsorption of fatty acids could be the reason [149]. An unbalance of n-3 PUFAs have been 
shown to modify the gut microbiota, were low level of n-3 PUFA most likely lower its 
metabolic activity [143].  An experimental study by Pachikian and colleagues showed that
malabsorption could be related to altered microbial fermentation [143]. They even suggested 
that such fermentation is related to endotoxemia, a potentially very important cause of 
systemic symptoms in these patients. Further studies of the potential pathological role of 
intestinal dysfunction in IBS are highly warranted. 
5.4 Effect of seal oil on non-gastrointestinal complaints
Non-gastrointestinal, systemic complaints are prevalent in patients with subjective food 
hypersensitivity (paper II). In the present thesis, besides high scores on gastrointestinal 
problems, the patients presented high scores of SHC from different organ systems, as assessed 
by the SHC Inventory. Musculoskeletal complaints, tiredness/fatigue, sleep problems and
anxiety were the most prominent non-gastrointestinal complaints (paper II). Unexplained, 
gastrointestinal complaints like abdominal pain, bloating and diarrhea may be considered as 
more defined and ‘genuine’ complaints than the more diffuse non-gastrointestinal complaints. 
But based on our findings, non-gastrointestinal complaints represent a problem of high
relevance, and the high proportion of patients with subjective food hypersensitivity that 
suffers from SHC, especially musculoskeletal complaints and tiredness/fatigue, suggests that 
SHC and subjective food hypersensitivity may share pathophysiological mechanisms. Thus it 
might be valuable to assess SHC in future studies. Patients with subjective food 
hypersensitivity and IBS have previously been found to have impaired QoL [150,151]. The 
patients in the present thesis also reported considerably impaired QoL. Unfortunately, we did 
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not have a control group in this explorative, open study (paper II), but the baseline total sum 
score of the QoL (28.0) reported in the present thesis [152] is comparable with that reported in 
the study of Arslan and colleagues (27.4) [26], were the QoL of patients with SHC was 
significantly impaired compared to controls (13.5). Considering the patients’ complex 
symptomatology, including both gastrointestinal and systemic symptoms, and the fact that 
their complaints often remain unexplained, impaired QoL was highly expected in the present 
thesis.  
It is generally assumed that psychological factors, including anxiety, depression and stress, 
aggravate gastrointestinal disorders and play important roles in the pathogenesis of 
unexplained medical symptoms. However, Lind and colleagues have recently shown that 
psychological factors such as symptom-specific and general anxiety, and depression could 
explain only approximately 10 % of the variance in the patients’ symptom severity; hence, 90
% of the variance remained unexplained [33]. This also suggests psychological factors to be 
secondary as a consequence of long-lasting somatic complaints. Consistently, many patients
experience that a psychological explanation model is put forward in absence of somatic 
pathology.  A diagnosis of psychosomatic disorder is therefore often not well accepted, and 
many patients tend to seek alternative medicine when not receiving adequately medical care. 
Sensitization theories, like cognitive sensitization or cognitive bias, have been 
suggested to account for the development of, at least in part, medically unexplained 
conditions, and such psychobiological mechanisms could be involved in subjective food 
hypersensitivity as well. The patients are often constantly worried with heightened vigilance 
for specific symptoms, which may unreasonably activate their cognitive sensitization 
networks, leading to over-reporting of somatic sensations and misattribution of bodily 
symptoms. Cognitive bias, which is considered as a higher form of cognitive-emotional 
sensitization, may be the underlying neurobiological substrate for SHC reaching the level of 
somatisation [153]. Concerns and modern health worries (MHW) (e.g. air pollution, additives 
in food, X-rays, chemicals in household products, etc.) have been associated with SHC and 
rise in health care use. MHW may lead to misinterpretation of everyday complaints as 
physiological consequences of environmental factors, and this is often exacerbated by media’s 
overemphasis of high-risk and disease-related stories [154]. Although, patients with food 
hypersensitivity report considerably more SHC than healthy controls, Lind and colleagues 
found that sum score on the MHW scale did not significantly differ between the patients and 
49
controls [27].  Thus, concerns for modern living do not explain the high prevalence of SHC in 
patients with subjective food hypersensitivity.  
In the present thesis, the short-term treatment with seal oil significantly improved the 
patients’ non-gastrointestinal complaints from baseline, and the improvement maintained 
significant 30 days post-treatment. It is reasonable to believe that the beneficial effect of the 
seal oil treatment can be explained by the involvement of the n-3 LC-PUFAs in pain 
attenuation by inhibiting PGE2 production. Indeed, PGE2 is known to be involved in pain 
sensitization [155]. A possible placebo response cannot be ignored when interpreting the 
results from the seal oil studies (paper I+II). Still, the prolonged effect of the seal oil 
treatment, on both SHC and gastrointestinal complaints, is intriguing, and may indicate that 
the positive effect of seal oil is not alone an outcome due to placebo response. To confirm and 
further elucidate the findings objective measures must be included in further controlled 
studies.   
Medical unexplained symptoms, arising from different organs, often occur together, 
and may have common underlying pathology. Central sensitization is believed to be 
responsible for generation of symptoms in fibromyalgia [129]; a condition characterised by 
widespread chronic pain mainly of musculoskeletal origin, and also gastrointestinal 
complaints. In fact, of those patients with fibromyalgia, 30 % to 70 % have concurrent IBS
[156]. Interestingly, in a recently published study, Berstad and colleagues found that 71 % and 
85 % of patients with IBS and subjective food hypersensitivity reported symptoms suggestive 
of fibromyalgia/and or chronic fatigue, respectively. Thus, it is likely to believe that these 
multi-symptom conditions may have a common underlying cause. Multiple unexplained 
symptoms are often associated with psychosomatic models. But, more likely, psychological 
disturbances are a consequence rather than a cause. The story of the peptic ulcer disease 
comes to mind here; when eliminating the microbial factor (Helicobacter pylori), both 
psychological and somatic complaints disappeared [157].
5.5 The role of enterochromaffin cells
The secretory EC cells play an important role of the enteric neuroendocrine system in 
maintaining normal gut function. CgA and 5-HT are major secretory products which may 
reflect activation of the neuroendocrine system. Due to inconsistent and limited data, the
association between CgA and gastrointestinal pathophysiology, and the relevance of CgA as a 
biomarker for disease activity in IBS is still unclear. Elevated serum levels of CgA have been 
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reported in patients with PI-IBS [80]. However, the density of CgA+ cells in duodenal and 
colonic mucosa has been decreased in IBS patients [158].
In the present study (paper IV), serum CgA was significantly lower in the patients 
with subjective food hypersensitivity compared to the healthy controls, which corroborates 
with our previous results [81]. Sidhu et al., have reported abnormally elevated levels of serum 
CgA in a small proportion of their included patients with diarrhea predominant IBS [80].
However, they did not include healthy controls and in many of the patients with elevated 
CgA, the levels declined with time, which the authors explained with short-lived EC cell 
hyperplasia, as previously reported by Dunlop et al. [159]. Thus, it would be interesting to 
perform repeated measurements over time of both CgA and 5-HT in future studies. 
CgA serves as a pro-hormone for shorter peptide fragments with regulatory properties 
[160]. Fragments of CgA exert anti-microbial effects and may modulate gastrointestinal 
motility, sensitivity and barrier function [161,162]. The low levels of CgA demonstrated in 
the present study could be a consequence of alterations in the gut microbial flora in patients 
with subjective food hypersensitivity [163,164]. Intriguingly, Dlugoz et al., have recently 
demonstrated Chlamydia trachomatis antigens in enteroendocrine cells and macrophages of 
the small bowel in patients with IBS [165]. Although the clinical significance is yet unknown, 
this is an exciting finding that together with the present finding of low serum levels of CgA 
could imply an impairment of EC cell function in patients with subjective food 
hypersensitivity and IBS. El-Salhy and colleagues demonstrated decreased CgA-positive cells 
in biopsies from patients with IBS [158]. Thus, a decrease in number of CgA secretory cells 
could be a reasonable explanation for the low serum CgA found in the present study. This 
should be looked into in future studies.
Interestingly, increased levels of plasma somatostatin have been reported in IBS [166].
Also, infusion of somatostatin analogues has been found to decrease plasma CgA [167].
Somatostatin suppresses the release of several gastrointestinal hormones which affects 
motility and intestinal secretions, among others. Hypothetically, abnormal high secretion of 
somatostatin could account for the decreased level of serum CgA observed in our patients. 
Potential role of somatostatin in subjective food hypersensitivity should be further 
investigated. 
A recently published study by Öhman et al demonstrated increased fecal levels of CgA 
and secretogranins II and III (Sg II and Sg III) in patients with IBS [168]. The authors 
reported a negative correlation between the fecal levels of CgA, SgII and SgIII with colonic 
transit time, but the association between fecal granins and symptoms were weak. Also, SgII 
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was found to have good discriminative validity to positively identify IBS. This study adds to 
the body of evidence that there is a gastrointestinal component in the aetiology of IBS, but 
whether the granins represent a cause of the pathopysiology or merely reflect the phenotype 
of IBS is still unanswered. The fact that elevated levels of Cgs also have been reported in 
other diseases than IBS, complicate the use of Cgs alone as a biomarker of IBS. Cgs may be 
more eligible to reflect the activity of the enteroendocrine system, and serve as a biomarker 
for other bioactive secretion products, like 5-HT, that can affect the bowel function. CgA is an 
established biomarker for neuroendocrine tumors, and circulating CgA is assumed to reflect 
the neuroendocrine secretion in the body. When it comes to gastrointestinal disorders, it might 
be beneficial to include analysis of faeces and/or luminal fluids because this could probably 
better mirror the condition in the gastrointestinal tract, and thus enhance the understanding of 
gastrointestinal disturbances. With this respect, it should be clarified whether circulating CgA 
corresponds to luminal secretion of CgA.
One of the signaling molecules with an unambiguous physiological role in the enteric nervous 
system (ENS) is 5-HT, involved in several aspects of gut function, including secretion, 
motility and sensation. Release or leakage of 5-HT into the gut lumen has been demonstrated 
previously [169,170], but whether luminal 5-HT has any physiological function or is just an 
overflow phenomena is not clear. High systemic levels of 5-HT may cause symptoms 
resembling hypersensitivity reactions to food, such as diarrhea [171,172], nausea [173], or 
flushing and heart palpitations [174]. 5-HT has been implicated in several gastrointestinal 
disorders, including IBS [169], IBD [175] and food hypersensitivity [176]. 5-HT is 
commonly measured in blood platelets or in plasma, the latter being a poor matrix due to 
rapid degradation of 5-HT into 5-hydroxyindolacetic acid (5-HIAA). More than 95 % of 
plasma 5-HT is present in platelets, and studies assessing platelet 5-HT content in IBS 
patients are somewhat conflicting [177,178,179]. Alterations of 5-HT secretion within the gut 
are not necessarily reflected in the systemic circulation, and assessing 5-HT in gut tissue 
samples is therefore often considered as more accurate. However, considering the large 
surface of the gastrointestinal tract, biopsies can only give information from a small fragment 
of this huge area. Indeed, EC cell counts seem to vary a lot in different studies [180,181]. In 
the present thesis we propose a simple and less invasive sampling procedure in conjunction 
with a rapid technique for determination of 5-HT in gut lavage fluid (paper III). EC cells 
release 5-HT mainly from granules at the basal border, but studies have shown that EC cells 
are bipolar and that they are able to secrete 5-HT both basally, into the systemic circulation, 
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and apically, into to the gut lumen [62,63,64]. Our method enabled quantification of luminal 
EC cell secretion of 5-HT along the entire length of the small and large bowel. In the present 
study (paper IV), gut lavage 5-HT were found to be unaltered in patients with subjective food 
hypersensitivity, as compared to healthy controls. Patients with IBD had slightly higher mean 
level of 5-HT, but the difference was not significant. 
The high degree of variance in the 5-HT data may be due to high individual differences as 
well as a consequence of the pre-analytical sampling procedure. The use of gut lavage fluid 
for analytical purpose is quite unique. Based on our previous experience with the procedure 
[99,182], the first clear fluid passed per rectum was chosen because it was desirable with as 
little particles as possible to avoid analytical problems, but we acknowledge that the time 
point of sampling is not necessarily the same for each participant, as transit time may vary a 
lot. Also, the 5-HT release with time may differ between subjects, thus, one measurement in 
time may not be the optimal method. These aspects should be considered in further studies 
using the gut lavage procedure. The PEG solution used in the lavage procedure is a potent 
laxative that may act as a stimulant and induce secretion of 5-HT from the EC cells. But 
because the PEG-load was equal in all participants, it is unlikely that PEG-stimulated 
secretion of 5-HT has affected the outcome in a way that has masked possible differences in 
detected 5-HT content.
To check if the high degree of variance in the 5-HT measurements could be due to
analytical errors, we performed multiple runs of gut lavage fluid samples spiked with known 
5-HT concentration, and multiple runs of both patient and control samples. The results 
showed good reproducibility, and we concluded that the variance observed in the analyzed 
material could not be ascribed to the preparation of the samples nor the analytical technique.
The high variability observed in the present study, may be a factor of the number of 
participants, at least to a certain degree. An increase in number of patients and controls would 
most likely lower the variability of the data.
ELISA is a widely used technique, due to numerous available commercial kits applicable for a
variety of biological samples and its ability to detect low levels of the targeted analyte.
We wanted to compare our reported LCMS method to the ELISA technique. The 5-HT level 
in gut lavage fluid was measured using an enzyme immunoassay, following the manufacture’s 
intructions (Labor Diagnostica Nord GmbH & Co. KG, Nordhorn, Germany. Cat # BA 10-
0900). This particular assay was designed for analyzing serum, urine, platelets, plasma and 
cerebrospinal fluid. To our knowledge, no immunoassay exists for analyzing gut lavage fluid.
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The high degree of variability in the 5-HT data obtained from LCMS analysis, were also 
observed after performing the ELISA technique on the same set of samples. The graph in 
Figure 7 shows the dispersion of the 5-HT measurements obtained from patient with 
subjective food hypersensitivity (unpublished data).
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Figure 7. [5-HT] in gut lavage fluid from patients with subjective food hypersensitivity. The same set of samples 
was analyzed by ELISA and LCMS. Data are given as individual values with mean±SEM. Unpublished data.
The level of 5-HT in gut lavage fluid, from both patients and controls, were found to be 
considerable elevated when performing ELISA compared to the 5-HT data obtained by using 
our reported LCMS method (Figure 8). This preliminary study showed that ELISA 
overestimated the levels of 5-HT by a factor of 4 in both the patients and the controls data
when compared to LCMS. Indeed, overestimation is a well-known problem with enzyme 
immunoassay techniques, due to cross-reactivity. The analytical specificity is decreased when 
compounds similar to the target molecule are present, and in the case of 5-HT analysis 
compounds like tryptamine, melatonin, 5-HIAA and histidine may affect the quantitative 
outcome.
Although the ELISA and LCMS results were not significant at a confidence level of 95 %, it 
was observed an increase of 42 % and 33 % in the 5-HT level of the patients compared to the 
controls. The interesting findings of this unpublished preliminary study should be further 
investigated. 
The potential applicability of our reported LCMS/MS method to analyze other 
biomedical samples, like plasma, serum and urine, should be explored, together with
simultaneous determination of 5-HT and its metabolic related products.
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Figure 8. [5-HT] in gut lavage fluid from patients with subjective food hypersensitivity and healthy controls.
Data are given as mean±SEM. Unpublished data.
5.6 Determination of IS amount in quantification of 5-HT
Chromatographic techniques using the IS method have been applied in the determination of 5-
HT in a wide variety of biological samples. However, in the majority of studies there is no 
description regarding the strategies behind the selection of an optimal amount of IS, 
especially in cases where the analyte may have a wide span of concentrations. The most 
common strategy is trial and error methods or rule of thumb technique such as targeting the IS 
to the lower 1/3 of the calibration curve. The validity of the IS method relies on the 
assumptions of linearity of the detector towards both the analyte and the IS, but this is often 
not acknowledged. The potential applicability of a multivariate strategy to estimate an optimal 
concentration and a robust RF, which do not change with changes in the analyte and IS 
concentrations, has been proposed by Araujo et al. [89].
Figure 9, shows that between 2 and 12 μg/mL of 5-HT, a RF that vary between 0.035 
and 0.045, is obtained when the concentration of 5-CH3O-HT is varied from 2 and 20 μg/mL.
Concentrations exceeding 12 μg/mL cause a considerable variation of the RF with the 
concentration of IS and a remarkable lessening of the dynamic analytical range (Figure 9). 
The curvatures observed in Figure 9 are the result of interaction between 5-HT and 5-CH3O-
HT, which is generally ignored in analytical studies, and could affect the accuracy of the
determination. The estimation of concentration regions where the RF remains constant is vital 
in order to conform to the criteria of linearity of the detector towards the analyte and IS. 
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Paper IV demonstrates that application of the Doehlert design enables estimation of the 
interaction 5-HT/5-CH3O-HT and selection of an optimal amount of IS and a constant RF for 
analysing 5-HT, where the unknown levels of 5-HT are spanned over a wide range of 
concentrations.
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Figure 9. Response factor contour plot. The contours of constant responses were generated 
by simultaneously varying the concentrations of 5-HT and 5-CH3O-HT between 2 and 20 
μg/mL. GLF=gut lavage fluid.
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6. Conclusions 
The present thesis suggests that short-term duodenal seal oil administration alleviate both 
intestinal and extra-intestinal complaints in patients with subjective food hypersensitivity.
Impaired gastric accommodation seems to play a limited role in the pathogenesis of the 
condition. A possible role of n-3 LCPUFA on intestinal inflammation, vago-vagal reflexes, 
visceral sensitivity, mucosal leakage and intestinal microbiota should be further investigated.
Patients with subjective food hypersensitivity have lower circulating CgA levels as compared 
to healthy controls, which may indicate the involvement of the endocrine system in subjective 
food hypersensitivity, but the pathophysiologic role needs to be further elucidated.
The novel method for measuring 5-HT in gut lavage fluid by LCMS/MS demonstrated to be a 
useful approach for a rapid, simple and efficient quantification in a wide range of 
concentrations. The small amount of sample, the low solvent consumption and the high 
sample throughput (30 samples/day) are important features that make the present approach 
highly attractive to clinical trials involving the analysis of 5-HT in a large number of samples.
The relationship 5-HT/5-CH3O-HT is highlighted as an important factor that affects the 
validity of the RF and consequently the accuracy of the analysis. However, in the present 
study, levels of 5-HT in gut lavage fluid were unaltered in patients with subjective food 
hypersensitivity.
Taken together, the hypothesis-generating studies of the present thesis encourage further 
investigations on the respective roles of 5-HT, CgA and seal oil in the pathophysiology and 
therapy of subjective food hypersensitivity.
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